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Fig.　1　Clinical photographs (a-c) and histopathological studies (d, e). (a, right elbow; b, left 
elbow) At fi rst visit. (c) At 15 hours after fl uconazole intake. (d, e) The histopathological fi nd-
ings were consistent with FDE. (d, hematoxylin and eosin staining; original magnifi cation 





Fixed Drug Eruption Caused by
Fluconazole: A Case Report and
Mini-Review of the Literature
A fixed drug eruption (FDE) characteristically recurs
at the same site or sites each time the drug adminis-
tered.1 Acute lesions usually develop 30 minutes to 8
hours after drug administration as sharply margi-
nated, round or oval itchy plaques of erythema and
edema that become dusky violaceous or brown, and
sometimes vesicular or bullous.1 Antibacterial drugs,
non-steroidal anti-inflammatory drugs, barbiturates
and other tranquillizers, phenolphthalein and related
compounds are commonly implicated agents.1 How-
ever, oral antifungal agents are rarely associated with
FDE. Here, we report the case of a 34-year-old
woman diagnosed with FDE due to oral fluconazole
and review the 16 similar cases (including this one)
in the English language literature.2-16
A 34-year-old Canadian woman was referred to our
department for diagnosis of a slight pigmented
macule on the right elbow and faint erythema with
scale on the left elbow (Fig. 1a, b). She reported that
she had woken up with two red erythematous
macules with a burning sensation on the elbows 9
days earlier. With time, the macules faded and pig-
mentation developed. She described two similar epi-
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sodes in the same location that had occurred about 1
year and about 5 months ago, respectively. A FDE
was suspected on the basis of her history and skin
symptoms. She listed her only active medication as
naproxen, which she had taken in regular doses for
many years to reduce pain during menstruation.
Therefore, FDE due to naproxen seemed not to be
related to the eruption onset, judging from the timing
of medication. Irritation and pressure due to a habit
of propping the elbows on a desk were considered as
possible causes of the eruptions, but she denied the
habit itself. FDE due to other drugs and nutritional
supplements was still considered in a differential di-
agnosis. A skin biopsy obtained from faint erythema
on the left elbow showed intraepidermal lymphocytic
infiltrate and dyskeratotic cells in the epidermis, par-
tial liquefaction degeneration at the dermal-epidermal
interface, and mild lymphocytic infiltrate around
small vessels in the upper dermis, but no specific
findings from the middle dermis to the fatty tissue
(Fig. 1d) . Immunohistochemically, CD8 + T cells
were distributed along the epidermal basal layer (Fig.
1e). These histopathological findings were consistent
with FDE. At her second visit to our department, on
the basis of the suspicion of FDE, we asked about her
medication history, but she answered that she only
took naproxen during menstruation. As a precaution,
a patch test with naproxen was planned. On the day
before her third visit to our department, she took a
fluconazole 150 mg capsule to suppress the symp-
toms of vaginal candidiasis. Within 15 minutes after
taking fluconazole, she noticed erythema with a burn-
ing sensation on both elbows and remembered that
she had taken fluconazole irregularly for 3 years
when she felt discomfort in her vaginal area, and that
the 3 episodes of eruption corresponded with the
time of fluconazole intake. A physical examination
demonstrated well-circumscribed erythematous pla-
ques (Fig. 1c). Therefore, we diagnosed FDE due to
fluconazole alone, judging from the timing of medica-
tion.
Including our case, there have been 16 reports of
FDE due to fluconazole (16 patients) in the litera-
ture.2-16 These patients (2 males, 13 females, and 1
patient of unidentified gender) were aged 19 to 64
years old (mean 34.0, median 30.0 years old) and
most (78.6%) had used fluconazole for treatment of
candidiasis. The dosages of fluconazole at the time of
eruption onset ranged from 150 to 400 mg. The drug
eruption commonly occurred soon after intake of flu-
conazole (from 20 minutes to 2 days) and resolved
rapidly (over an average of 13.5 days) with discon-
tinuation of the drug with or without treatment for
the eruption. Patients were diagnosed with 0 to 15
similar episodes (mean, 3.4). The eruptions occurred
on various parts of the body and were mainly treated
with oral antihistamines and topical steroids, or were
observed without treatment in accordance with the
degree of severity. In 3 cases, the eruptions were
widely distributed over the face, trunk, and extremi-
ties and were treated with systemic steroids or ster-
oid pulse therapy. In 9 of 16 cases, skin biopsy was
performed for microscopic evaluation. A lymphocyte
transformation test was not discussed in any of the
cases. A positive patch test for fluconazole was re-
ported in 2 (33.3%) of 6 evaluable cases and an oral
challenge test was positive in all 7 evaluable cases. In
4 patients, reproduction of skin lesions was seen after
self-administration of fluconazole without medical ad-
vice.
In our case, the histopathological findings of skin
biopsy provided a clue for the diagnosis of FDE.
However, we were unable to obtain information from
the patient about the causative drug because she had
used fluconazole infrequently for short periods over 3
years and had not associated the drug with the skin
eruption. In the available reports, the sensitivity of a
patch test with fluconazole was low, whereas oral
challenge tests ( including self-administration) were
all positive, suggesting that this test is the most reli-
able method of diagnosis of FDE due to fluconazole.
However, the oral challenge test is generally consid-
ered unsafe, with Gupta and Thami 9 suggesting a
graded oral challenge with escalating doses until
FDE develops. In our case, an involuntary oral provo-
cation was positive, but the patient noticed that the
eruption was caused by fluconazole because we had
explained to her that drugs might have caused her
eruptions based on histopathological findings. Thus,
inquiries into medical history and potential explana-
tions for symptoms, in addition to skin biopsy, were
crucial for identification of FDE in this case. The case
also illustrates the importance of medical practitio-
ners paying attention to drugs such as fluconazole
that are used at low frequencies, but still may cause
FDE.
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